A regulatory requirement non-interventional study to monitor the safety and effectiveness of Glyxambi (empagliflozin/linagliptin, 10/5mg, 25/5mg) in Korean patients with type 2 diabetes mellitus

First published 06/12/2021

Last updated 02/07/2025

EU PAS number:

EUPAS44579

Study

Finalised

Documents

Study protocol

Updated protocol

Eng Esgliteo PMS_1275-0028-protocol_v5.0_28Oct2022_clean_Redacted.pdf

First published: 03/02/2025

English (483.39 KB - PDF)View document

Study results

Study report

1275-0028-study-report-v3-0_02Aug2024_Final_Redacted.pdf

English (164.87 KB - PDF)View document

Other information

Secondary tabs